Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Rating of “Moderate Buy” by Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $14.90.

A number of brokerages have commented on VNDA. Jefferies Financial Group increased their price objective on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a report on Wednesday, December 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. B. Riley Financial upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Truist Financial assumed coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, March 5th. They set a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright raised their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a report on Monday, February 23rd.

Insider Transactions at Vanda Pharmaceuticals

In other news, CFO Kevin Patrick Moran sold 42,442 shares of Vanda Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,995.34. Following the completion of the sale, the chief financial officer directly owned 411,380 shares of the company’s stock, valued at approximately $3,402,112.60. This trade represents a 9.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Timothy Williams sold 42,434 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,929.18. Following the sale, the senior vice president owned 377,450 shares of the company’s stock, valued at approximately $3,121,511.50. The trade was a 10.11% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 314,342 shares of company stock worth $2,583,985. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in shares of Vanda Pharmaceuticals by 8,629.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 29,158 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 28,824 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of Vanda Pharmaceuticals by 51.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,829 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 14,836 shares during the last quarter. Susquehanna Portfolio Strategies LLC lifted its holdings in Vanda Pharmaceuticals by 35.1% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 150,427 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 39,087 shares during the period. Balyasny Asset Management L.P. bought a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $601,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $521,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Trading Down 17.6%

Shares of VNDA opened at $7.07 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The company has a market cap of $417.61 million, a price-to-earnings ratio of -1.89 and a beta of 0.55. The stock has a fifty day moving average price of $7.76 and a two-hundred day moving average price of $6.32. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. Analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.